Engineered Immune Molecules Show Preclinical Promise
Early animal and cell data from BriaCell suggest a path for broader cancer immunotherapy, but human trials have not yet begun.
Updated on Nov. 6, 2026 in Biotech

BriaCell Therapeutics and its subsidiary BriaPro Therapeutics presented four preclinical immunotherapy posters at the SITC 41st Anniversary Annual Meeting in Phoenix, Arizona, November 4-8, 2026. The findings are preclinical and research-stage; none of the described candidates is an approved or commercially available product.
Why it matters
The posters cover an off-the-shelf cellular immunotherapy platform (Bria-OTS+), a CD28 co-stimulatory molecule (BP-80), and a PD-L1-targeting construct (TILsRx-001), reflecting active work on making cancer immunotherapy more broadly applicable across tumor types. The data support continued development across multiple cancer indications, but remain laboratory and animal-stage evidence.
The preclinical figures include a 49-fold increase in PD-L1 binding affinity for TILsRx-001 relative to a construct lacking CD80 mutations, and a 130-fold PD-L1 binding gain for CD80-Fc over wild-type CD80. BP-80 showed no treatment-related pathological findings at its 50 mg/kg/dose No Observed Effect Level in a four-week study, though human relevance remains untested.
The players
BriaCell Therapeutics
A Philadelphia and Vancouver-based clinical-stage biotechnology company developing cancer immunotherapies, including the Bria-OTS+ off-the-shelf cellular platform.
BriaPro Therapeutics
A subsidiary of BriaCell focused on the BP-80 CD28 co-stimulatory and TILsRx-001 programs in immunotherapy research.
SITC
The Society for Immunotherapy of Cancer, whose annual meeting is a major venue for immuno-oncology research presentations.
The details
Bria-OTS+ is an off-the-shelf immunotherapy platform, meaning it is designed to be manufactured in advance rather than custom-made from each patient's cells. In cell-based experiments, priming and boosting enhanced immune cells' ability to kill cancer cells across multiple tumor lines, and the activity persisted through repeated tumor challenges and in cells derived from breast and prostate cancer patients. BP-80 acts on CD28, a receptor that provides a second activating signal to T cells, and in cell assays it counteracted CTLA-4, a molecule that normally dampens T-cell activity; CD80 variants were generated through structure-guided engineering, meaning designs informed by the three-dimensional shape of the proteins.
Timeline
November 4-8, 2026: SITC 41st Anniversary Annual Meeting in Phoenix, Arizona
November 6, 2026: Bria-OTS+ and TILsRx-001 poster presentations
November 7, 2026: BP-80 and CD80 variant poster presentations
The Tech Race
Checkpoint-pathway immunotherapy, built on PD-1/PD-L1 and CTLA-4 blockade, is the established approach in immuno-oncology, and these preclinical posters position BriaCell's engineered molecules as a next step within that same field. The company's off-the-shelf Bria-OTS+ platform represents a different manufacturing strategy from the patient-specific cell therapies that dominate much of the current race.
These findings are preclinical and not yet available to patients; no clinical trial timeline or pricing was announced in the source. Readers should treat the posters as early research rather than a near-term treatment option.
The takeaway
The strongest signal here is the engineering approach: molecules tuned for binding affinity and tested for tolerability in primates. Watch for whether BriaCell advances any of these candidates into human clinical trials, which would be the first test of whether the preclinical results hold.
Further reading
For broader context on where these findings sit, explore the latest Biotech coverage.
More information
Copies of the four SITC 2026 posters are available on the BriaCell scientific publications page.
Source note: This article includes information reported by The Manila times.





